FOXO4-DRI Before and After: Nothing Human Was Measured

What the studies actually measured

This site deals in numbers, so it is worth listing the endpoints rather than describing them loosely.

Endpoint	How it was measured	Organism
Senescent-cell burden	p16-driven bioluminescent reporter, imaged in the living animal	Mouse
Fur density	Photographed and scored	Mouse
Physical fitness	Performance testing	Mouse
Renal function	Biochemical markers	Mouse
Cell viability	In-vitro assays against other senolytics	Cultured cells
Anything in a person	Not measured	None

Fur density is the row that produced the circulating images. It is a legitimate, visible, photographable proxy for tissue health in an ageing mouse with a defined genetic background, controlled diet and short lifespan. It was chosen because it is measurable in that model, not because it corresponds to a human outcome.

Why no timeline can be given

A legitimate before-and-after requires a person, a defined dose, a defined interval, a measured outcome, and ideally a control group. Every element is missing.

There is no defined dose, because none has been established in humans. There is no expected interval, because no human pharmacokinetics exist and nobody knows how long the peptide persists in a person. There is no validated outcome measure available outside a laboratory: bioluminescent reporters and senescence markers are not things anyone assesses at home. And there is no control group, so even a genuine individual change could not be attributed to the compound.

This page therefore offers no timeline. Not because information is withheld, but because producing one would mean inventing it.

How to read what is circulating

What you encounter	What it usually is	How to check
Transformation photos	Reused images, often unrelated fitness content	Reverse image search
Mouse comparison images	Genuine, from the 2017 paper	Trace to the published figure
Week-by-week timelines	Authored content, no study behind it	Ask what was measured, by whom
Forum accounts	Unverified material, uncontrolled conditions	Note what else was changing
Clinic marketing	Promotion of an unapproved compound	No clinic can lawfully dispense it

The forum category deserves particular care, and not because the writers are dishonest. Someone experimenting with an unapproved research peptide is typically also training, changing diet and often using several compounds at once. Attributing a change to one variable in that setting is not possible even in good faith.

One thing you can actually verify

If you want a number about this compound that is genuinely checkable, it is not an outcome. It is the contents of the vial.

Kovera Labs assayed batch 55-05260628 at 11.41 mg of net content. MZ Biolabs assayed lot 55-01260229 at 8.30 mg. Both were labelled 10 mg. That is a documented, verifiable, 37% difference between two batches of the same product, and it is the kind of fact that is worth more than any photograph.

Match the certificate to your lot and put the assayed figure into the calculator rather than the label.

Frequently Asked Questions

Are there real FOXO4-DRI before and after pictures?expand_more

Of mice, yes, from the 2017 Cell paper showing restored fur density in aged animals. Of humans, no. No person has received this peptide in a registered study.

How long until results appear?expand_more

There is no answer to give. No human outcome has been measured on any timescale and no human pharmacokinetic data exists to reason from. Any timeline you find was authored rather than observed.

Can I tell whether it is working?expand_more

No. The endpoints used in the studies require laboratory techniques such as senescence markers and bioluminescent reporters. There is no home-observable measure of senescent-cell clearance.

Why do sites show transformation photos anyway?expand_more

Because the query attracts traffic and images are easy to source elsewhere. Reverse image searching usually locates the original context, frequently unrelated fitness or cosmetic content.

Worked Examples — Related Compound Protocols

Apply this guide to real protocols. Each linked page includes a live reconstitution calculator and titration schedule.

Epitalon dosage protocol

Epitalon (also Epithalon, Epithalamin tetrapeptide) is a synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG) developed by Vladimir Khavinson by directed synthesis from the amino-acid composition of bovine pineal extract Epithalamin [1][2]. It is the most extensively studied of the Khavinson peptide bioregulators, with documented effects on telomerase activation, telomere elongation, melatonin restoration, and lifespan extension in rodent and Drosophila models [3][4][5]. Khavinson and colleagues showed Epitalon activates telomerase in human fetal somatic cell cultures with observable telomere elongation, and Anisimov demonstrated 12–13% lifespan extension in mice and 11–16% in fruit flies [6]. Standard research dosing is 5–10 mg subcutaneously per day for 10–20 consecutive days, repeated 2–3 times yearly. Epitalon is registered as a peptide bioregulator in Russia but is not approved by the FDA, EMA, or MHRA; outside Russia it is a research-only compound. Human clinical evidence is limited to Russian observational use in age-related disorders, with reports of restored circadian melatonin rhythms, improved immune markers, and normalized neuroendocrine function.

Open protocolarrow_forward

NAD dosage protocol

NAD+ (nicotinamide adenine dinucleotide) is the central redox and signaling cofactor for hundreds of enzymes including sirtuins (SIRT1–7), poly(ADP-ribose) polymerases (PARPs), and CD38, with intracellular concentrations declining substantially with age across human tissues [1][2]. Sinclair, Imai, and colleagues established sirtuins as NAD-dependent deacetylases that regulate longevity, metabolism, and DNA repair, and showed that restoring NAD+ levels through precursor supplementation can reverse age-related metabolic decline in mice [3][4]. Yoshino and colleagues demonstrated in a randomized clinical trial that nicotinamide mononucleotide (NMN) at 250 mg/day improves muscle insulin sensitivity in prediabetic women [5]. NAD+ itself is administered as a research and integrative medicine intervention at 100–500 mg subcutaneously or intramuscularly, or 250–1000 mg by slow intravenous infusion over 1–4 hours, in cycles. NAD+ is sold as a supplement (oral, sublingual, injectable) but the FDA has not approved NAD+ injection for any therapeutic indication. NAD+ precursors (NR, NMN) have FDA NDI status as dietary supplements but are not approved drugs.

Open protocolarrow_forward

BPC-157 dosage protocol

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide (GEPPPGKPADDAGLV) derived from a partial sequence of a larger Body Protection Compound originally isolated from human gastric juice by Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s [1][2]. Across more than 30 years of preclinical work, BPC-157 has been shown to accelerate the healing of tendon, ligament, muscle, bone, skin, gastrointestinal tract, and cornea through pro-angiogenic mechanisms involving VEGF receptor 2 (VEGFR2) activation, nitric oxide synthase upregulation through the Akt-eNOS axis, ERK1/2 signaling, and modulation of the dopaminergic and serotonergic systems [3][4]. Chang and colleagues demonstrated in the Journal of Applied Physiology that BPC-157 promotes tendon healing by enhancing tendon outgrowth, cell survival, and migration in tendon fibroblast cultures, and that it upregulates growth hormone receptor expression in those cells [5][6]. BPC-157 is not FDA approved and remains a research peptide. Typical research dosing is 250 to 500 mcg/day subcutaneously, with cycles of 4 to 8 weeks.

Open protocolarrow_forward

References & Citations

[1]
Baar MP, Brandt RMC, Putavet DA, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017;169(1):132-147.e16.View source →
[2]
Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression. Circulation. 2023.View source →